Open AccessLow tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project
Author(s) -
Matthew A Spinelli,
David V. Glidden,
Warren Rodrigues,
Guohong Wang,
Michael S. Vincent,
Hideaki Okochi,
Karen Kuncze,
Megha Mehrotra,
Patricia Defechereux,
Susan Buchbinder,
Robert M. Grant,
Monica Gandhi
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002135
Subject(s) - urine , medicine , seroconversion , interquartile range , immunoassay , pre exposure prophylaxis , dosing , emtricitabine , point of care testing , urinary system , cohort , human immunodeficiency virus (hiv) , men who have sex with men , immunology , viral load , antibody , antiretroviral therapy , syphilis
We examined the relationship between urine tenofovir (TFV) levels measured with a novel immunoassay, which permits point-of-care testing, with HIV seroconversion and objective adherence metrics in a large preexposure prophylaxis (PrEP) demonstration project.